Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA (2020 - 2025)

Historic EBITDA for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to -$2.8 million.

  • iSpecimen's EBITDA fell 9312.03% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year decrease of 2370.78%. This contributed to the annual value of -$12.5 million for FY2024, which is 1261.41% down from last year.
  • iSpecimen's EBITDA amounted to -$2.8 million in Q3 2025, which was down 9312.03% from -$1.0 million recorded in Q2 2025.
  • Over the past 5 years, iSpecimen's EBITDA peaked at -$942644.0 during Q1 2021, and registered a low of -$6.0 million during Q4 2024.
  • Over the past 5 years, iSpecimen's median EBITDA value was -$2.2 million (recorded in 2023), while the average stood at -$2.4 million.
  • As far as peak fluctuations go, iSpecimen's EBITDA tumbled by 40114.78% in 2021, and later surged by 5034.56% in 2025.
  • Quarter analysis of 5 years shows iSpecimen's EBITDA stood at -$2.0 million in 2021, then decreased by 7.35% to -$2.1 million in 2022, then crashed by 34.06% to -$2.9 million in 2023, then tumbled by 110.62% to -$6.0 million in 2024, then soared by 54.01% to -$2.8 million in 2025.
  • Its EBITDA stands at -$2.8 million for Q3 2025, versus -$1.0 million for Q2 2025 and -$1.7 million for Q1 2025.